Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- Portola
Pharmaceuticals, Inc. announced today that it will present clinical
and preclinical data on its oral Factor Xa inhibitor and on its
intravenous and oral ADP receptor antagonist at the XXI Congress of
the International Society of Thrombosis...
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis
SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo,
Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM
(Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase
2 trial looking at recombinant nematode anticoagulant protein c2
(rNAPc2) in patients with acute coronary sy...
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- Portola
Pharmaceuticals, Inc. announced positive Phase II data on its lead
compound, PRT054021, an oral Factor Xa inhibitor, today at the XXI
Congress of the International Society on Thrombosis and Haemostasis
(ISTH) in Geneva, Switzerland. The EXPERT t...
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,
Inc. (Nasdaq GM:NTEC) today announced that two poster presentations
were presented with its collaborative partner, Novo Nordisk A/S,
relating to GlycoPEGylated recombinant Factor VIIa at the XXIst
Congress of the International Societ...
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results
from the RE-NOVATE(TM) trial demonstrated that oral dabigatran
etexilate once daily, administered for an average of 33 days, was
non-inferior to enoxaparin, also administered for an average of 33
days, in preventing venous thromboemb...
Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
...gs were presented today at the XXII International Society on Thrombosis and
haemostasis Congress in Boston. Edoxaban is being developed solely by Daiichi Sankyo C...ic medicinal products in non-surgical patients. Journal of Thrombosis and
haemostasis 2005;3: 692-694.
...
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
...of Leuven will present
additional data from the earlier successful Phase I studies at the XXII
Congress of the International Society on Thrombosis and
haemostasis (ISTH) on
July 15, 2009 in Boston.
Patrik De Haes, CEO of ThromboGenics commented, "We are very happy that
this important study with TB-402 is ...
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
...
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as
haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that ma...
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
...t al. Definition of major bleeding in clinical
investigations of antihemostatic medicinal products in non-surgical patients.
Journal of Thrombosis and
haemostasis 2005;3: 692-694.
2. Jorgensen, H.S., Nakayama, H, Reith, J. et. al. Acute stroke with
atrial fibrillation. Stroke 1996;27: 1765-1769.
...
New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
...ncluding the most advanced products within the area of insulin
delivery systems. In addition, Novo Nordisk has a leading position within
areas such as
haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets pharmaceutical
products and services that ma...
Portola Pharmaceuticals Announces Positive Phase II Results for
PRT054021 for Prevention of Venous Thromboembolism Following Total
Knee Replacement Surgery
...ncing the compound into further clinical trials. Data
from EXPERT will be presented at the XXI Congress of the
International Society on Thrombosis and
haemostasis in Geneva,
Switzerland (July 6-12, 2007).
"There is a tremendous need for a once a day, oral anticoagulant
to replace and improve upon current thera...
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon
Expanded Understanding of Lead Compound Mechanism of Action
...alog compounds under development for
non-ophthalmic indications. Dr. Mousa's talk will be presented at
the XXI International Society on Thrombosis and
haemostasis (ISTH)
Congress in Geneva, Switzerland on July 9, 2007. The ISTH holds its
congress every other year and the organization includes 2,800
thrombosis, h...
Liraglutide provides significantly better glucose control than
insulin glargine in phase 3 study
...ncluding the most advanced products within the area
of insulin delivery systems. In addition, Novo Nordisk has a
leading position within areas such as
haemostasis management,
growth hormone therapy and hormone replacement therapy. Novo
Nordisk manufactures and markets pharmaceutical products and
services that ma...
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes
Using Self-Adjusted Dosing Starting With Once-Daily Insulin
Treatment Levemir
...cluding the most advanced products within the
area of insulin delivery systems. In addition, Novo Nordisk
has a leading position within areas such as
haemostasis management,
growth hormone therapy and hormone replacement therapy. Novo
Nordisk manufactures and markets pharmaceutical products and
services that m...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
...ial data presented today at the XXI International
Society on Thrombosis and
haemostasis (ISTH) Congress demonstrate
that once-daily rivaroxaban achieved superior e...- presented at ISTH in 2005, and published in the
Journal of Thrombosis and
haemostasis in 2005 and 2006, and the
additional once-daily ODIXa HIP study published i...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
...Bleeding
Rates
GENEVA, July 8, 2007 - Late-breaking Phase III clinical trial
data presented today at the XXI International Society on Thrombosis
and
haemostasis (ISTH) Congress demonstrate that once-daily
rivaroxaban (Xarelto®) achieved superior efficacy in the
prevention of venous thromboembolism (VTE) in...
International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
...ents at Risk for Venous Thromboembolism in the Acute Hospital
Care Setting) study presented today at the XXIst International
Society on Thrombosis and
haemostasis (ISTH) congress in
Geneva.
VTE is a preventable disease which contributes significantly to
morbidity and mortality among patients hospitalized for a...
New Information on the Potential of Plasmin Shared at ISTH Congress
...AL-05-00018, was
presented by Talecris Biotherapeutics, Inc.
(http://www.talecris.com) this week at the XXIst International
Society for Thrombosis and
haemostasis (ISTH) Congress in Geneva,
Switzerland. The information included new data and updates on
continuing research and development of Plasmin as a potential...